Zoetis Inc. (NYSE:ZTS) Position Boosted by Valeo Financial Advisors LLC

Valeo Financial Advisors LLC lifted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 1.1% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 8,028 shares of the company’s stock after purchasing an additional 91 shares during the period. Valeo Financial Advisors LLC’s holdings in Zoetis were worth $1,568,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Webster Bank N. A. lifted its position in shares of Zoetis by 89.1% during the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after purchasing an additional 82 shares during the last quarter. Quarry LP lifted its holdings in Zoetis by 273.2% in the second quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after acquiring an additional 153 shares during the last quarter. Neo Ivy Capital Management bought a new position in Zoetis in the fourth quarter worth about $40,000. LRI Investments LLC bought a new position in Zoetis in the first quarter worth about $43,000. Finally, Hazlett Burt & Watson Inc. lifted its holdings in Zoetis by 60.7% in the first quarter. Hazlett Burt & Watson Inc. now owns 270 shares of the company’s stock worth $46,000 after acquiring an additional 102 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

NYSE ZTS opened at $190.08 on Friday. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09. The firm has a market capitalization of $86.12 billion, a PE ratio of 37.20, a P/E/G ratio of 2.95 and a beta of 0.89. The company’s 50 day simple moving average is $188.07 and its 200 day simple moving average is $176.20.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The business had revenue of $2.36 billion for the quarter, compared to analyst estimates of $2.31 billion. During the same quarter last year, the business earned $1.41 earnings per share. The business’s revenue for the quarter was up 8.3% on a year-over-year basis. As a group, equities research analysts forecast that Zoetis Inc. will post 5.83 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be paid a dividend of $0.432 per share. The ex-dividend date is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.91%. Zoetis’s dividend payout ratio is presently 33.86%.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on ZTS shares. Stifel Nicolaus raised their target price on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, September 18th. BTIG Research raised their target price on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. JPMorgan Chase & Co. raised their target price on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday. Piper Sandler raised their price target on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Finally, Argus upgraded shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Zoetis presently has an average rating of “Buy” and an average price target of $221.44.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.